Patent · US Active

Ready to use liquid RECK formulation

US10952963B2 · kind B2 · utility

3Cited by

2References

19Claims

0Family size

Assignee

QuVa Pharma Inc. · US

Inventors

Travis A. Leeah · Sugar Land, US
Jianping Chen · Shanghai, CN

Key dates

Filing date	Apr 11, 2019
Grant date	Mar 23, 2021
Priority date	—
Expiry date	Jul 20, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein is a ready-to-use liquid formulation comprising ropivacaine, epinephrine, clonidine, and ketorolac (collectively referred to as RECK). Also disclosed herein is a process for preparing the RECK-containing liquid formulation, as well as methods for using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.